Recce Pharmaceuticals (ASX: RCE) has received Human Research Ethics Committee approval to expand and advance its Australian trial of RECCE 327 topical gel to a ...
Recce Pharmaceuticals (ASX: RCE) has received Human Research Ethics Committee approval to expand and advance its Australian trial of RECCE 327 topical gel for Diabetic Foot Infection. This crucial development marks the trial's progression to a pivotal Phase 3. The move signifies…
Market Samachar is a news aggregator. This article was originally published by smallcaps.com.au. Tap the button above to read the full story on their site.